文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

中药复方归鹿仙对低预后高龄女性体外受精-胚胎移植结局的影响:一项前瞻性、多中心、随机双盲研究方案

Effect of traditional Chinese medicine formula Guilu Xian on in vitro fertilization and embryo transfer outcome in older women with low prognosis: study protocol for a prospective, multicenter, randomized double-blind study.
PubMed 文献 · Trials · 2021-12-13

本研究为前瞻性、多中心、随机双盲临床试验,拟纳入120例在中国3家公立医院接受IVF或ICSI的低预后不孕患者,随机分为归鹿仙组(n=60)与安慰剂组(n=60),两组均采用拮抗剂方案促排卵,比较获卵总数、受精率、临床妊娠率、胚胎质量、胚胎种植率及早期自然流产率。

要点

  • 归鹿仙组与安慰剂组各60例,均采用拮抗剂方案促排卵。
  • 主要比较获卵总数、受精率、临床妊娠率、胚胎质量、胚胎种植率及早期自然流产率。
  • 试验注册于中国临床试验注册中心ChiCTR1900028255,注册日期2019年12月16日。

核心结论

  • 研究将探讨中药复方归鹿仙对低预后高龄女性IVF-ET结局的影响。

研究设计与样本

  • 前瞻性、多中心、随机双盲临床试验,拟纳入120例在中国3家公立医院接受IVF或ICSI的低预后不孕患者。
  • 患者随机分为归鹿仙组(n=60)与安慰剂组(n=60),两组均采用拮抗剂方案促排卵。
  • 两组患者均从月经周期第2至4天服药至取卵日。

主要发现

  • 原文为研究方案,未报告研究结果。

关键数值与推荐

  • 比较两组获卵总数、受精率、临床妊娠率、胚胎质量、胚胎种植率及早期自然流产率。
  • 试验注册号ChiCTR1900028255,注册日期2019年12月16日。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: In recent years, the prevalence of infertility has significantly increased and has become a global reproductive health problem. The female ovarian reserves have been shown to decrease progressively with an increase in age. Besides, the rate of embryo implantation and clinical pregnancy also decreases. Traditional Chinese medicine has been widely applied in assisted reproductive technology. It is reported to have a significant influence on improving the quality of oocytes, improving endometrial receptivity, increasing clinical pregnancy rate, reducing pregnancy-related complications, etc. Therefore, this study will investigate the effect of Guilu Xian, a traditional Chinese medicine formula on IVF-ET outcome in older women with low prognosis. METHODS AND ANALYSIS: This trial is a prospective, multicenter, randomized double-blind clinical trial. A total of 120 infertile patients with low prognosis and receiving IVF or ICSI in 3 public hospitals in China will be randomly divided into two parallel groups: Guilu Xian group (n = 60) and placebo group (n = 60). Patients in both groups will be treated with antagonist regimens to promote ovulation, and all the patients will be required to take the medication from the 2nd to 4th day of the menstrual cycle to the day of egg retrieval. A comparison of the total number of oocytes obtained, the fertilization rate, clinical pregnancy rate, embryo quality, embryo implantation rate, and early spontaneous abortion rate between the experimental group and the placebo group will be performed. TRIAL REGISTRATION: Chinese Clinical Trials Registry ChiCTR1900028255 . Registered on 16 December 2019.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Ma Y, Cao X, Song J, et al. Effect of traditional Chinese medicine formula Guilu Xian on in vitro fertilization and embryo transfer outcome in older women with low prognosis: study protocol for a prospective, multicenter, randomized double-blind study. Trials. 2021. PMID: 34903263. doi:10.1186/s13063-021-05867-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。